Kymera stock falls as Jefferies lowers price target on program shifts

Kymera Therapeutics (KYMR) stock declined after Jefferies lowered its price target following partner Sanofi's decision to discontinue advancement of the IRAK4 degrader KT-474 in Phase 2, opting instead to prioritize the next-generation KT-485. Despite this setback, Kymera secured a new collaboration with Gilead Sciences for CDK2 molecular glues, a potential $5 billion opportunity, and anticipates Phase 1b data in Q4 2025 for its lead STAT6 degrader KT-621, which Jefferies views as a potential 'oral Dupixent.' Meanwhile, Sanofi (SNY) maintains strong financial health and a robust pipeline, with confidence in Dupixent and Beyfortus growth, while also licensing its STAT6 program to Nurix Therapeutics (NRIX) for $15 million.

Analysis

Kymera Therapeutics (KYMR) experienced a stock decline following its partner Sanofi's decision to halt the advancement of the Phase 2 IRAK4 degrader KT-474, instead prioritizing a next-generation molecule, KT-485, with Phase 1 trials now delayed until 2026. This pipeline setback, which prompted Jefferies to lower its price target on KYMR to $64.00 from $66.00, is partially counterbalanced by significant positive developments. Kymera has initiated a new collaboration with Gilead Sciences to develop CDK2 molecular glues, a venture Jefferies estimates could represent a greater than $5 billion opportunity in oncology. Furthermore, Kymera's lead program, the STAT6 degrader KT-621, is advancing, with pivotal Phase 1b data in atopic dermatitis expected in Q4 2025, positioning it as a potential 'oral Dupixent'. For Sanofi, this move reflects active pipeline management, supported by its robust $116.62 billion market capitalization and strong financial health. Sanofi also continues to build its inflammation portfolio by licensing a STAT6 program from Nurix Therapeutics for a $15 million fee. Sanofi's near-term outlook is buoyed by confident guidance for Dupixent and projected peak sales of €2 billion to €3 billion for its RSV antibody Beyfortus, though it faces mixed results in other areas, such as the Phase III trials for itepekimab in COPD.

Key Decisions for Investors

• Investors in Kymera should weigh the near-term pipeline delay of its IRAK4 program against the significant long-term potential of the new Gilead collaboration and the pivotal Q4 2025 data for its STAT6 degrader, KT-621.
• For Sanofi, the strategic pipeline adjustments demonstrate a focus on best-in-class assets, but investors should monitor the upcoming Phase III results for amlitelimab and commercial performance of Dupixent and Beyfortus as key value drivers.
• The events underscore the binary risk inherent in biotech partnerships; while the KT-474 halt creates a headwind for Kymera, the new Gilead deal and Sanofi's broader strategy highlight the importance of portfolio diversification and next-generation asset development.